Late-Onset Anti-GABAB Receptor Encephalitis: Clinical Characteristics and Outcomes Differing from Early-Onset Patients.
Tangna Sun,Daidi Zhao,Gejuan Zhang,Yue Huang,Jia Guo,Wen Jiang,Rui Jia,Maynur Maimaiti,Jianguo Liu,Ning Bu,Zunbo Li,Yaping Yan,Xiaoyan Zhang,Chenjing Sun,Cong Zhao,Xiaotao Jia,Baoyi Mao,Hui Tian,Yan Liu,Zheng Chen,Zilian Fan,Xiaoyan Guo,Jiarui Lu,Kaixi Ren,Hongzeng Li,Jun Guo
DOI: https://doi.org/10.1212/nxi.0000000000200131
2023-01-01
Abstract:Background and Objectives Existing evidence indicates anti-GABAB receptor encephalitis (GABA(B)R-E) seems to occur more commonly later in life, yet the age-associated differences in clinical features and outcomes are not well determined. This study aims to explore the demographic, clinical characteristics, and prognostic differences between late-onset and early-onset GABABR-E and identify predictors of favorable long-term outcomes. Methods This is an observational retrospective study conducted in 19 centers from China. Data from 62 patients with GABA(B)R-E were compared between late-onset (aged 50 years or older) and early-onset (younger than 50 years) groups and between groups with favorable outcomes (modified Rankin scale (mRS) <= 2) and poor outcomes (mRS >2). Logistic regression analyses were applied to identify factors affecting long-term outcomes. Results Forty-one (66.1%) patients experienced late-onset GABA(B)R-E. A greater proportion of males, a higher mRS score at onset, higher frequencies of ICU admission and tumors, and a higher risk of death were demonstrated in the late-onset group than in the early-onset group. Compared with poor outcomes, patients with favorable outcomes had a younger onset age, a lower mRS score at onset, lower frequencies of ICU admission and tumors, and a greater proportion with immunotherapy maintenance for at least 6 months. On multivariate regression analysis, age at onset (OR, 0.849, 95% CI 0.739-0.974, p = 0.020) and the presence of underlying tumors (OR, 0.095, 95% CI 0.015-0.613, p = 0.013) were associated with poorer long-term outcomes, whereas immunotherapy maintenance for at least 6 months was associated with favorable outcomes (OR, 10.958, 95% CI 1.469-81.742, p = 0.020). Discussion These results demonstrate the importance of risk stratification of GABA(B)R-E according to age at onset. More attention should be paid to older patients especially with underlying tumors, and immunotherapy maintenance for at least 6 months is recommended to achieve a favorable outcome.